Skip to main content
. Author manuscript; available in PMC: 2021 Oct 10.
Published in final edited form as: Adv Drug Deliv Rev. 2021 Jul 29;176:113901. doi: 10.1016/j.addr.2021.113901

Figure 3.

Figure 3

In vitro approaches currently exhibit a trade-off between throughput capacity and physiological and biological complexity. The feasibility for high-throughput data collection decreases as the in vitro model design mimics physiological and biological characteristics of the lungs in the effort to recapitulate more closely in vivo models, and humans in particular.